CEL-SCI Announces $10 Million Equity Financing Facility

Apr 12, 2001, 01:00 ET from CEL-SCI Corporation

    VIENNA, Va., April 12 /PRNewswire/ -- CEL-SCI CORPORATION (Amex:   CVM), a
 developer of novel products for the treatment of cancer and infectious
 diseases, today announced that it has entered into a binding agreement with a
 private investment fund to provide the Company with up to $10 million in
 equity financing.
     Under the two-year agreement, CEL-SCI will have the right, but not the
 obligation, to obtain as much as $10 million through the issuance of common
 stock, at a discount to market, to the investor in a series of periodic sales.
 Subject to certain volume limitations, the amount and minimum price per share
 of each sale are at the sole discretion of the Company.
     The sales are subject to the satisfaction of a number of conditions,
 including the effectiveness of a registration statement filed with the
 Securities and Exchange Commission covering the resale of shares covered by
 the equity line and certain related warrants.
     CEL-SCI plans to use the proceeds from sales under this facility for
 research and development, product manufacturing, working capital and/or other
 general purposes.
     CEL-SCI Corporation is a biopharmaceutical company whose mission is to
 harness the immune system to combat disease.
 
     "CEL-SCI press releases are available through Company News On-Call by fax,
 (800) 758-5804, Ext. 445563, or at http://www.cel-sci.com on the Internet."
 
     When used in this report, the words "intends," "believes," "anticipated"
 and "expects" and similar expressions are intended to identify forward-looking
 statements.  Such statements are subject to risks and uncertainties, which
 could cause actual results to differ materially from those projected.  Actual
 results might differ materially from these statements due to risks and
 uncertainties, including the price of CEL-SCI's stock at the time of any
 sales, the extent of CEL-SCI's capital requirements, and the cost and
 availability of capital from other sources.  More complete descriptions of the
 risks applicable to CEL-SCI appear in the Company's documents filed with the
 Securities and Exchange Commission and available on request from the company.
 CEL-SCI disclaims any intent or obligation to update these forward-looking
 statements.
 
 

SOURCE CEL-SCI Corporation
    VIENNA, Va., April 12 /PRNewswire/ -- CEL-SCI CORPORATION (Amex:   CVM), a
 developer of novel products for the treatment of cancer and infectious
 diseases, today announced that it has entered into a binding agreement with a
 private investment fund to provide the Company with up to $10 million in
 equity financing.
     Under the two-year agreement, CEL-SCI will have the right, but not the
 obligation, to obtain as much as $10 million through the issuance of common
 stock, at a discount to market, to the investor in a series of periodic sales.
 Subject to certain volume limitations, the amount and minimum price per share
 of each sale are at the sole discretion of the Company.
     The sales are subject to the satisfaction of a number of conditions,
 including the effectiveness of a registration statement filed with the
 Securities and Exchange Commission covering the resale of shares covered by
 the equity line and certain related warrants.
     CEL-SCI plans to use the proceeds from sales under this facility for
 research and development, product manufacturing, working capital and/or other
 general purposes.
     CEL-SCI Corporation is a biopharmaceutical company whose mission is to
 harness the immune system to combat disease.
 
     "CEL-SCI press releases are available through Company News On-Call by fax,
 (800) 758-5804, Ext. 445563, or at http://www.cel-sci.com on the Internet."
 
     When used in this report, the words "intends," "believes," "anticipated"
 and "expects" and similar expressions are intended to identify forward-looking
 statements.  Such statements are subject to risks and uncertainties, which
 could cause actual results to differ materially from those projected.  Actual
 results might differ materially from these statements due to risks and
 uncertainties, including the price of CEL-SCI's stock at the time of any
 sales, the extent of CEL-SCI's capital requirements, and the cost and
 availability of capital from other sources.  More complete descriptions of the
 risks applicable to CEL-SCI appear in the Company's documents filed with the
 Securities and Exchange Commission and available on request from the company.
 CEL-SCI disclaims any intent or obligation to update these forward-looking
 statements.
 
 SOURCE  CEL-SCI Corporation